Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech, privacy and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Kevin Bercimuelle-Chamot, Alessandro Cerri, Anastasiia Kyrylenko, Nedim Malovic, Marcel Pemsel and Anna Maria Stein.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Antonios Baris (Book Review Editor), Rose Hughes (PatKat), Tian Lu (Asia Correspondent) and Chijioke Okorie (Africa Correspondent).

InternKat: Jocelyn Bosse.
Home / Eleonora Rosati / events / IPKat readers / life sciences / Life Sciences Strategy Summit on IP and Exclusivity / patents / Life Sciences Strategy Summit on IP & Exclusivity returns to Munich with special IPKat readers’ discount

Life Sciences Strategy Summit on IP & Exclusivity returns to Munich with special IPKat readers’ discount

- , , , , ,
Kat summit

The IPKat is pleased to inform readers that this year’s Life Sciences Strategy Summit on IP & Exclusivity will be held on 9, 10, 11 October 2023 in Munich (Germany).

This year’s summit follows the launch of the Unified Patent Court (UPC) and will inter alia allow participants to understand the industry’s reaction to the new court system and have candid discussions with European life science intellectual property experts.

As stated by the organizers, the highlights of this year’s edition are as follows:
  • Cross-industry end-user panel discussing the opening of the UPC and the life science industry response with Chr. Hansen and IFF alongside a judicial perspective with 4 legal judges and 3 technical judges
  • IP Minds Roundtable discussions on: Antibody Case Law, Biosimilar IP Considerations, Arrow Declaration, Clinical Trials and Patent Strategy, AI and Life Science Patents, Trade Secrets vs Patent Protection, FTO: Best Practices
  • 1-day dedicated event on SPCs entitled: Global SPC & PTE Forum 2023 with speakers from the European Commission, a Pan-European Patent Office Panel, the EPO, MSD, Polpharma Group and Adalvo
  • Building a practical Exclusivity Strategy and understanding the upcoming changes from the European Commission with speakers from Venable, Alkermes, Pieris Pharmaceuticals, BioNTech and Adalvo
The agenda can be accessed here, while the list of speakers is here.

New to this year’s edition is also the Global SPC & PTE Forum 2023, a one-day event dedicated to the key legislative changes and case law regarding SPC and PTE protection in Europe and beyond.

Readers can also watch this video interview with Thomas Böhmer, Head of IP at Pieris Pharmaceuticals, for a glimpse into his work and the topics that will be covered in October.

The IPKat has also negotiated a special discount for readers. To save 10% please use VIP code IPKAT at checkout. For more information and to register, please click here.
Life Sciences Strategy Summit on IP & Exclusivity returns to Munich with special IPKat readers’ discount Life Sciences Strategy Summit on IP & Exclusivity returns to Munich with special IPKat readers’ discount Reviewed by Eleonora Rosati on Tuesday, August 01, 2023 Rating: 5

1 comment:

  1. AnonymousTuesday 1 August 2023 at 14:47:00 GMT+1

    Why the need to register to access the agenda?

    ReplyDelete

All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.

It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.

Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html

Subscribe to: Post Comments ( Atom )
Powered by Blogger.